Literature DB >> 19854478

Renal masses herniating into the hilum: technical considerations of the "ball-valve phenomenon" during nephron-sparing surgery.

Brett Lebed1, Shraddha D Jani, Alexander Kutikov, Kevan Iffrig, Robert G Uzzo.   

Abstract

OBJECTIVES: To describe our technique to recognize and resect renal tumors "ball-valving" into the sinus. Partial nephrectomy (PN) offers a functional advantage over radical nephrectomy for many cases of localized renal cell carcinoma. However, PN is underutilized particularly in anatomically challenging cases. Often unrecognized is the tendency for central renal tumors to herniate into the renal sinus.
METHODS: From our prospective kidney cancer database, we identified 36 patients who underwent open, laparoscopic, or robotic PN for solitary localized renal cell carcinoma herniating into the renal sinus.
RESULTS: Axial and reformatted radiographs were reviewed for all renal hilar lesions. Intraoperative techniques include hilar dissection, establishment of a sinus plane allowing tumor and parenchymal retraction, reduction of the tumor out of the sinus, resection, and repair. Mean preoperative lesion size was 3.8 cm. Indications for PN included 15 of 36 (42%) absolute, 13 of 36 (36%) relative, and 2 of 36 (6%) reoperative PN. No procedure was converted to radical nephrectomy. Of the 36 PN, 5 (14%) were performed using a minimally invasive approach and no minimally invasive surgery procedures were converted to open. No patient required renal replacement.
CONCLUSIONS: Recognition of the tendency for hilar masses to herniate or "ball-valve" into the renal sinus is essential for effective PN of central tumors. By using our technique, we have demonstrated success in nephron-sparing surgery with minimal intraoperative complications and favorable postoperative outcomes in patients with central tumors herniating into the renal sinus. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19854478      PMCID: PMC2992985          DOI: 10.1016/j.urology.2009.06.098

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  19 in total

1.  Long-term results of nephron sparing surgery for localized renal cell carcinoma: 10-year followup.

Authors:  A F Fergany; K S Hafez; A C Novick
Journal:  J Urol       Date:  2000-02       Impact factor: 7.450

2.  Progression and survival after renal-conserving surgery for renal cell carcinoma: experience in 104 patients and extended followup.

Authors:  W R Morgan; H Zincke
Journal:  J Urol       Date:  1990-10       Impact factor: 7.450

3.  3-dimensional volume rendered computerized tomography for preoperative evaluation and intraoperative treatment of patients undergoing nephron sparing surgery.

Authors:  D M Coll; R G Uzzo; B R Herts; W J Davros; S L Wirth; A C Novick
Journal:  J Urol       Date:  1999-04       Impact factor: 7.450

4.  Conservative surgery of renal cell tumors in 140 patients: 21 years of experience.

Authors:  F Steinbach; M Stöckle; S C Müller; J W Thüroff; S W Melchior; R Stein; R Hohenfellner
Journal:  J Urol       Date:  1992-07       Impact factor: 7.450

5.  Management of small solitary unilateral renal cell carcinomas: impact of central versus peripheral tumor location.

Authors:  K S Hafez; A C Novick; B P Butler
Journal:  J Urol       Date:  1998-04       Impact factor: 7.450

6.  Role of nephron sparing surgery in the treatment of centrally located renal tumors.

Authors:  Giuseppe Martorana; Santo Lupo; Eugenio Brunocilla; Sergio Concetti; Michele Malizia; Emmanuele Vece
Journal:  Arch Ital Urol Androl       Date:  2004-06

7.  Parenchymal sparing surgery for central renal tumors in patients with hereditary renal cancers.

Authors:  Darrel E Drachenberg; Othon J Mena; Peter L Choyke; W Marston Linehan; McClellan M Walther
Journal:  J Urol       Date:  2004-07       Impact factor: 7.450

8.  Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy.

Authors:  Bradley C Leibovich; Michael L Blute; John C Cheville; Christine M Lohse; Amy L Weaver; Horst Zincke
Journal:  J Urol       Date:  2004-03       Impact factor: 7.450

9.  Surgical enucleation for renal cell carcinoma.

Authors:  A C Novick; H Zincke; R J Neves; H M Topley
Journal:  J Urol       Date:  1986-02       Impact factor: 7.450

10.  Hand assisted laparoscopic partial nephrectomy for peripheral and central lesions: a review of 30 consecutive cases.

Authors:  James A Brown; Scott G Hubosky; Leonard G Gomella; Stephen E Strup
Journal:  J Urol       Date:  2004-04       Impact factor: 7.450

View more
  5 in total

Review 1.  The role of minimally invasive surgery in multifocal renal cell carcinoma.

Authors:  Serge Ginzburg; Robert G Uzzo; Alexander Kutikov
Journal:  Curr Urol Rep       Date:  2012-06       Impact factor: 3.092

Review 2.  Nephron-sparing surgery in renal cell carcinoma: current perspectives on technical issues.

Authors:  Javier González; José Manuel Cózar; Antonio Gómez; Cristina Fernández-Pérez; Manuel Esteban
Journal:  Curr Urol Rep       Date:  2015-02       Impact factor: 3.092

Review 3.  Current status of robot-assisted partial nephrectomy.

Authors:  Jose M Reyes; Marc C Smaldone; Robert G Uzzo; Rosalia Viterbo
Journal:  Curr Urol Rep       Date:  2012-02       Impact factor: 3.092

4.  Residual renal function after partial or radical nephrectomy for renal cell carcinoma.

Authors:  David Chapman; Ron Moore; Scott Klarenbach; Branko Braam
Journal:  Can Urol Assoc J       Date:  2010-10       Impact factor: 1.862

5.  Neoadjuvant combination of pazopanib or axitinib and programmed cell death protein-1-activated dendritic cell-cytokine-induced killer cells immunotherapy may facilitate surgery in patients with renal cell carcinoma.

Authors:  Zhiling Zhang; Longbin Xiong; Zeshen Wu; Huiming Liu; Kang Ning; Yulu Peng; Chunping Yu; Ya Ding; Desheng Weng; Jianchuan Xia; Lijuan Jiang; Shengjie Guo; Hui Han; Fangjian Zhou; Pei Dong
Journal:  Transl Androl Urol       Date:  2021-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.